Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
On April 12, 2017, Neuralstem, Inc. (the Company) announced that
a new cohort of four patients will be added to its ongoing Phase
1 human clinical trial evaluating the safety and feasibility of
using NSI-566 spinal cord-derived neural stem cells to repair
chronic spinal cord injury. A copy of the press release is
attached to this report as Exhibit 99.01.
The information contained in this Item 7.01 to this Current
Report on Form 8-K and the exhibit attached hereto pertaining to
this item shall not be deemed to be filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall such information or such exhibits be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing. The
information set forth in the exhibits to this Form 8-K relating
to this item 7.01 shall not be deemed an admission as to the
materiality of any information in this report that is required to
be disclosed solely to satisfy the requirements of Regulation FD.
| Item 9.01 | Financial Statement and Exhibits. |
|
Exhibit No. |
Description |
|||
|
99.01 |
Press Release dated April 12, 2017 |
About Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. (NASDAQ:CUR) Recent Trading Information
Neuralstem, Inc. (NASDAQ:CUR) closed its last trading session 00.00 at 4.76 with 108,829 shares trading hands.